The St Louis Business Journal (Free subscription) | 07/24/2008
Pfizer Inc.'s profit more than doubled in the second quarter, reflecting growth in international pharmaceutical sales, the drug giant said Wednesday. (PFE)
Seeking Alpha (Free subscription) | yesterday
J Clinton Hill submits: Pfizer (PFE) is hard pressed to generate growth as it deals with lack of a significant pipeline and stands to lose Lipitor’s exclusive patent in March 2010. After a series of disappointments with Torcetrapib, Asenapine, Promune, Exubera, Dalbavancin and Tremelimumab, many investors have abandoned the stock. To address its bottom line over the near-term, PFE is currently...
Seeking Alpha (Free subscription) | yesterday
Mike Huckman submits: Previously I posited a theory that the weak American economy might be hurting sales growth of erectile dysfunction drugs . The drugs are so pricey and may not be covered by insurance, so I wondered whether men might be cutting their pills in half and/or not filling their expensive prescriptions if they're having to tighten their belts. Complete Story »
Seeking Alpha (Free subscription) | 07/24/2008
Mike Huckman submits: On the Pfizer (PFE) earnings conference call yesterday morning, Chairman and CEO Jeff Kindler kicked things off by calling this a "time of great uncertainty in the world economy and capital markets and significant challenges in our industry." As a Pfizer PR person pointed out in an email following my earnings story on "Squawk on the Street" yesterday morning, worldwide...
Law Blog - WSJ.com (Free subscription) | 07/24/2008
Pfizer's profit more than doubled as international sales offset generic competition in the U.S. Glaxo posted a 3% drop in net and will cut costs.
Pharmalot (Free subscription) | yesterday
Pfizer was handed a record $200,000 fine after its reps wrongly told doctors that a rival drug was dangerous, and the penalty formed part of a record $1.8 million of fines handed down to some of the world’s largest drugmakers, including Glaxo and Roche, by the Medicines Australia trade group, The Age reports. Many of the [...]
USA Today (Free subscription) | 07/23/2008
Wednesday, Pfizer said quarterly earnings more than doubled on higher sales of its prescription drugs and lower expenses, but ...
New York Times (Free subscription) | 07/23/2008
Pfizer beat Wall Street expectations, saying its profit more than doubled as restructuring charges declined and the weak dollar helped lift overseas revenue.
Miami Herald (Free subscription) | 07/23/2008
Drug maker Pfizer says its second-quarter profit more than doubled as restructuring charges declined and the weak dollar helped lift overseas revenue.
Business Wire (Free subscription) | yesterday
Zacks Analyst Blog Highlights:Halliburton Company,AK Steel Holding Corp., Robert Half International Inc., Energizer Holdings, Inc. and Pfizer Inc. CHICAGO--()--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include:...
Law Blog - WSJ.com (Free subscription) | 07/23/2008
Pfizer's net income more than doubled amid cost-cutting and lower restructuring charges. Wyeth posted a 6.4% decrease in net income, weighed down by restructuring costs.
New York Times (Free subscription) | 07/24/2008
Although all three firms face major threats from generic competition, results show that demand for medicines is holding up well at a time of economic downturn.
Market Watch (Free subscription) | 07/23/2008
Pfizer, the world’s largest drugmaker, reported that its second-quarter profit more than doubled, due largely to a favorable currency exchange rate and lower costs.
Reuters (Free subscription) | 07/23/2008
NEW YORK (Reuters) - Pfizer Inc on Wednesday said second-quarter earnings more than doubled on higher sales of its prescription drugs, lower expenses and overseas sales that were boosted by the weak dollar.
Fool.com (Free subscription) | 07/24/2008
In fairness, Pfizer took its lumps in years like 2005, when a strong dollar pinched its earnings, without complaining or switching to "constant currency" valuation metrics to distort its financial picture. Still, it's hard not to notice that the biggest constituent of Pfizer's revenue growth this quarter was a seven-percentage-point contribution from changes in the dollar relative to...
